A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Combination With Gemcitabine In Patients With Chemotherapy Naive Advanced Pancreatic Cancer Preceded By A Phase 1 Portion
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Survival (OS)
Time in days from randomization to date of death due to any cause. OS was calculated as the death date minus the the date of randomization plus 1. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
Baseline of Phase 2 to death or until at least 1 year after the randomization of the last participant
No
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A4061016
NCT00219557
July 2005
March 2008
Name | Location |
---|---|
Pfizer Investigational Site | Blendora, California 91740 |
Pfizer Investigational Site | Clearwater, Florida 33761 |
Pfizer Investigational Site | Columbia, Missouri 65201 |
Pfizer Investigational Site | Asheville, North Carolina 28801 |
Pfizer Investigational Site | Farmington, Connecticut 06030-3805 |
Pfizer Investigational Site | Milwaukee, Wisconsin 53215 |
Pfizer Investigational Site | Omaha, Nebraska 68198 |
Pfizer Investigational Site | Bangor, Maine 04401 |